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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYDetailed knowledge of cell-surface proteins for isolating well-defined populations of human pluripotent stem cells (hPSCs) would
significantly enhance their characterization and translational potential. Through a chemoproteomic approach, we developed a cell-
surface proteome inventory containing 496 N-linked glycoproteins on human embryonic (hESCs) and induced PSCs (hiPSCs). Against
a backdrop of human fibroblasts and 50 other cell types, >100 surface proteins of interest for hPSCs were revealed. The >30 positive and
negativemarkers verified here by orthogonal approaches provide experimental justification for the rational selection of pluripotency and
lineage markers, epitopes for cell isolation, and reagents for the characterization of putative hiPSC lines. Comparative differences
between the chemoproteomic-defined surfaceome and the transcriptome-predicted surfaceome directly led to the discovery that STF-
31, a reported GLUT-1 inhibitor, is toxic to hPSCs and efficient for selective elimination of hPSCs from mixed cultures.INTRODUCTION
Human pluripotent stem cells (PSCs) can differentiate
into nearly all somatic cell types present in the human
body and can generate clinically relevant numbers of cells
for regenerative medicine. The advent of hiPSCs, derived
from somatic cells by the exogenous expression of
defined transcription factors, has overcome ethical issues
associated with human embryonic stem cells (hESCs)
and, when derived from the patient, may avoid immuno-
logical complications. Human iPSCs have also opened
new avenues of research for the study of basic disease
mechanisms and development of informative model sys-
tems for drug discovery. Although promising, significant
limitations to the therapeutic use of hiPSCs remain unre-
solved. These include interline variations ranging from
inconsistent transcription factor expression and differen-
tial DNA methylation to sporadic point mutations and
chromosomal defects that affect in vitro differentiation,
tumorigenicity, and potential clinical applications (Feng
et al., 2010; Gore et al., 2011; Robinton and Daley,
2012). Moreover, current tests of hiPSC potency rely on
extensive in vitro differentiation tests, in vivo teratomaSteassays in rodents (Maherali and Hochedlinger, 2008;
Robinton and Daley, 2012) or bioinformatic and gene
expression assays (Bock et al., 2011; Mu¨ller et al., 2011),
which cannot be practically implemented into high-
throughput hiPSC line generation designed to limit inter-
line variability.
The lack of suitable cell-surfacemarker panels and related
affinity-based reagents for isolating high-quality hiPSCs
and well-defined progeny significantly restricts our ability
to minimize interline variability and employ hiPSCs for
regenerative medicine. Although guidelines and animal-
free methods have been proposed for the derivation and
characterization of therapeutic and good manufacturing
practice compliant hiPSCs (Buta et al., 2013; Funk et al.,
2012; Maherali and Hochedlinger, 2008; Mu¨ller et al.,
2010), no system is available to overcome safety and effi-
cacy issues of hiPSCs analogous to immunophenotyping
of blood lineages for identifying and isolating hematopoi-
etic stem cells (HSCs). Although markers such as SSEA-3,
SSEA-4, Tra-1-60, and Tra-1-81 aid in the identification of
hPSCs, few known surfacemarkers and application-specific
antibodies are restricted to the pluripotent state (Damjanov
et al., 1982; Kannagi et al., 1983; Lowry et al., 2008).m Cell Reports j Vol. 3 j 185–203 j July 8, 2014 j ª2014 The Authors 185
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Human Pluripotent Stem Cell SurfaceomeMoreover, as cell-surface proteins play critical roles in inter-
and intracellular communication, a better understanding
of the cell surface should inform the dynamic interplay
between cells and their microenvironment that ultimately
regulates how hPSCs interact with and respond to external
cues and differentiate in a directed manner (Lian et al.,
2013; Murry and Keller, 2008; Yan et al., 2005). Coupling
this functional relevance with the fact that more than
60% of US Food and Drug Administration-approved drug
therapies target membrane proteins, and 38% of disease-
related proteins are membrane associated (Cheng et al.,
2012; Yildirim et al., 2007), we aimed to generate a new
resource derived from a targeted analytical approach, Cell
Surface Capture (CSC) technology (Gundry et al., 2009,
2012; Hofmann et al., 2010; Wollscheid et al., 2009) that
experimentally verifies extracellular domains of surface
proteins. This resource, through its direct protein measure-
ments, will foster the identification of proteins and
epitopes useful for immunophenotyping and facilitate
the identification of drugs that target hPSCs. The value
of this resource is exemplified by the identification of pro-
teins capable of marking live hPSCs and the identification
of a small molecule inhibitor, STF-31, that allows for selec-
tive depletion of hPSCs from hESC and hiPSC-derived
progeny.RESULTS
Human Pluripotent Cell-Surface N-Glycoproteome
We employed the chemoproteomic CSC technology to
directly measure and define the average N-glycoprotein
surface proteome of hiPSCs, hESCs, and human fibroblasts
(hFibs) (Figure 1A). Biotin labeling of glycoproteins was
specific to the cell surface (Figure 1B), and all reported gly-
coproteins detected by this technology were identified by
peptides containing a deamidation (resulting from
PNGaseF cleavage after glycosylation-based enrichment)
at the consensus amino acid sequence motif (NxS/T)
for N-glycosylation (Figure 1C). Altogether, 496 N-glyco-Figure 1. CSC Technology Workflow
(A) Simplified schematic workflow of the CSC technology.
(B) Immunofluorescence image of hESC colony after cell-surface biotin
biotinylation. Blue, DNA (Hoechst); green, Biotin (Streptavidin-FITC
(C) Annotated MS/MS spectrum of one peptide from Interleukin-17 re
sequence motif (highlighted), which collectively represents the data
final protein list.
(D) Bioinformatics workflow for merging multiple data types fo
characterization.
(E) Graphical representation of the coverage of N-glycopeptides a
‘‘generically’’ annotated membrane protein without GO terms linking
ethz.ch/protter) (Omasits et al., 2013).
Steproteins were identified with a false discovery rate
(FDR) %5% on the cell surface of hPSCs (Figure 2; Table
S1 available online), composed of 92 cluster of differentia-
tion (CD) and 411 non-CD molecules, including predicted
transmembrane (92%), Glycosylphosphatidylinisotol
(GPI)-linked (4%), and extracellular matrix proteins (4%).
A complete catalog of extracellular glycopeptides and gly-
cosites is provided in Tables S2, S3, and S4, and data were
compiled into ProteinCenter (Figure 1D). These data pro-
vide direct experimental evidence regarding surface locali-
zation, which is critical for proteins whose subcellular
localization is unknown or ambiguous, and transmem-
brane orientation for proteins whose structure has not yet
been resolved. LRRN1, a protein with generic
‘‘membrane’’ annotation but not currently linked to gene
ontology (GO) terms for the cell surface or plasma
membrane (Figure 1E), and FAM216A, a protein with previ-
ously unannotated subcellular localization (UniProt), are
examples of where CSC technology data provide new
experimentally derived localization information, and
immunostaining corroborates the surface localization of
these proteins, thus confirming the validity of CSC-tech-
nology-based annotations. The discovery approach used
in this study is limited to the identification of N-glycosy-
lated peptides; therefore, it is not uncommon for proteins
to be identified by a single N-glycopeptide (e.g., proteins
with only a single N-glycosite in their amino acid
sequence). Additional confidence in all protein identifica-
tions is provided by the use of high mass accuracy mass
spectrometry during data acquisition and the implemen-
tation of three independent search algorithms for data
processing. Examples of proteins that were identified by a
single N-glycopeptide, but for which we provide positive
antibody-based evidence include ADCYAP1R1, EFNA3,
FAM216A, HTR2C, IL27RA, NPR1, PVRL2, and SLC7A3.
Compared to published proteomic studies of hPSCs (i.e.,
compilation of 15 studies; herein referred to as the ‘‘PSC
proteome’’ (Gundry et al., 2011), 158 proteins (31% of
the current data) have not been reported among the
>9,500 proteins previously described in hPSCs, and 106labeling via the CSC technology, illustrating selective extracellular
). Scale bar, 200 mm.
ceptor D illustrating the deamidation (N115) within the N-glycosite
‘‘tag’’ used for filtering out non-cell-surface contaminants from the
r identifying cell-surface proteins of interest for downstream
nd confirmation of extracellular domain for LRRN1, a previously
it to the cell surface. Image generated using Protter (http://wlab.
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Figure 2. The hPSC Cell-Surface N-Glycoproteome
All 496 N-glycoproteins identified in hPSCs are listed in order of their increasing mRNA expression (top left to right bottom). For simplicity,
the microarray values represented here are an average among all replicates of H9 hESC and KB3 hiPSC. The fill color of each box is
representative of transcript abundance (unlogged microarray value), where white indicates values below 200. The border color indicates
Gene Ontology (GO) protein annotations of cell-surface localization. Proteins represented by white boxes with red borders are examples of
proteins identified via the CSC technology but would otherwise be unlikely to be categorized as potential surface markers due to their low
transcriptional expression and lack of surface localization GO annotation.
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Human Pluripotent Stem Cell Surfaceomeproteins (21% of the current data) were identified in only a
single other study within the PSC proteome (Gundry et al.,
2011). Consistent with the PSC phenotype, EPCAM and
ALPL were observed exclusively in hPSCs, whereas others
such as Thy1 (CD90) were also observed in fibroblasts.188 Stem Cell Reports j Vol. 3 j 185–203 j July 8, 2014 j ª2014 The AuthorsSurface Proteome Comparisons Reveal Putative
hPSC-Restricted Markers
Putative markers for positive selection were identified by
comparing the surface proteome of hPSCs with those
from hFibs, nondiseased somatic cell types (n = 12) and
Stem Cell Reports
Human Pluripotent Stem Cell Surfaceomecancer cell types (n = 38) present in the Cell Surface Protein
Atlas (see Table S5). As selection criteria, putatively
restricted PSC markers were required to be absent from
hFibs, present in no more than three somatic cell types,
but were not limited by the number of cancer cell types
inwhich theywere observed, as similarities between cancer
and pluripotent cells are known (Kim et al., 2010; Ratajczak
et al., 2013; Riggs et al., 2013). Two hundred proteins met
these selection criteria, and 90 of these were uniquely iden-
tified in this study, whereas 47 others were reported in only
one other proteomic study (Table S6). Of these 200 PSC-
restricted proteins, 48 were uniquely identified in hPSCs
when compared to other cells within the Atlas (Table 1).
We provide surface immunostaining for eight of the 90
hPSC-restricted surface proteins uniquely identified
here (ADCYAP1R1, EFNA3, FAM216A, FGFR3, HTR2C,
IL17RD, NPR1, and OPCML; Figures 3 and 4), as well as
for ten hPSC-restricted proteins observed among the 15
previous proteomic reports (CXADR [seven other studies],
EPHA1 [five]; IL27RA [one]; LINGO1 [one]; LRRN1 [three];
PTPRZ1 [four]; SEMA6A [six]; SPINT1 [three]; SLC7A3
[four]; andUNC5D [one]). Eight additional cell-surface pro-
teins (ACVR2A, F3, ICAM3, ITGA6, NRCAM, PCDH1,
PVRL2, and UNC5C) not hPSC-restricted are also illus-
trated in Figures 3 and 4 and S1. In all cases, antibody-based
analyses were consistent with surface localization deter-
mined by the CSC technology. Moreover, costaining of
fixed cells illustrates that surface expression colocalizes to
OCT4-positive cells (Figure 3A), and altogether we demon-
strate the ability of 28 antibodies to successfully stain live
hPSCs either by immunocytochemistry (Figures 3B and
S1) or flow cytometry and confirm the absence of hPSC-
restricted markers on hFibs (Figure 4).
Surface Proteome Comparisons Reveal Negative hPSC
Markers
Negative selection markers are not well established for
hPSCs, even though positive selection carries the risk of
functional changes with antibody binding (e.g., CD3 anti-
body binding promotes T cell activation; Berg et al., 1998).
To identify putative markers for negative cell selection, we
focused on proteins present in hFib, present in six or more
nondiseased cell types in the CSPA, and which were not
observed in hPSCs via the CSC technology. This led to
the classification of 15 proteins as potential negative
markers of selection of hPSCs from coculture with hFibs
(Table 1). Flow cytometry confirmed the absence of three
selected proteins (DPP4 [CD26], NRP1 [CD304], COLEC12)
on hESCs and hiPSCs that were highly immunoreactive on
hFibs (Figure 4C). Moreover, we classified aminopeptidase
N (ANPEP, CD13) as a negative marker of pluripotency,
consistent with a recent report showing successful fluores-
cence activated cell sorting (FACS) of hiPSCs after reprog-Steramming (Kahler et al., 2013). These data also reveal
discrepancies between mouse and human PSCs. We previ-
ously identified NRP1, COLEC12, and CD13 in mouse
PSCs (Gundry et al., 2012), but, based on CSC technology
and antibody-based analyses here and (Kahler et al.,
2013), these surface proteins are absent from hPSCs.
Theoretical Surface Proteome versus CSC Technology
A comparison of the theoretical surface proteome based on
transcriptomic data to that defined by the CSC technology
underscores why proteomic strategies are essential for
providing direct evidence for the location and quantity of
cell-surface proteins (Figure 2). For example, proteins such
as ADCYAP1R1, EFNA3, HTR2C, NPR1, and UNC5Dwould
have been overlooked as potential surfacemarkers if relying
solely on transcriptomic approaches. By microarray, these
transcripts were detected at only background/threshold
levels (Table S1), even though robust protein levels were de-
tected using Ab-based techniques. Moreover, proteins such
as FAM216A may be overlooked as potential surface
markers as their GO terms do not specifically indicate
they are localized to the plasma membrane. Surface pro-
teins are affected by nontranscriptional mechanisms of
regulation (e.g., surface proteins shuttle among cellular
compartments, protein half-life independent of mRNA
expression timeline (Kristensen et al., 2013; Vogel andMar-
cotte, 2012), and these types of posttranscriptional regula-
torymechanismsmaybebroadly important asother surface
proteins identified here with similarly low mRNA levels
have known critical functions in early embryonic develop-
ment or pluripotency (e.g., LPAR2, 3, and 4 [Liu and Arm-
ant, 2004] and TLR2 [Taylor et al., 2010]). Additionally,
the microarray data may highlight a number of other PSC-
restricted proteins with functional relevance to pluripo-
tency due to their relatively high mRNA levels (e.g.,
APLP2, FRAS1, FTH1, GPC4, GCNT2, NLGN4X, PTPRZ1,
SEMA6A, SLC38A2, SLC7A3, and VCAN). Although several
cell-surface-annotated proteins with microarray values
above 5,000 were not detected via CSC technology, further
inspection reveals that GO term assignments for these can
be misleading (e.g., TUBB3, MYH9 have GO terms
including plasma membrane, even though these are not
cell-surface-accessible proteins), and others do not contain
an N-glycosylation site (e.g., ENO1, KARS, and SETP2) ex-
plaining why they were not detected in the current study,
though alternative targeted proteome strategies such as
Cys-CSC and K-CSC (Hofmann et al., 2010) would likely
capture them if they are truly located at the cell surface.
hPSC Cell-Surface Protein Resource Enables Rational
Selection of Drug Targets
The facilitated glucose transporter family is one subset of
proteins that came to light as a result of the perceivedm Cell Reports j Vol. 3 j 185–203 j July 8, 2014 j ª2014 The Authors 189
Table 1. Cell-Surface Proteins of Interest
Gene Symbol
for Protein
Mouse
ESC
Mouse
iPSC hESC hiPSC
Human
Fibroblasts
No. of Nondisease
Human Cell Types
in Cell Surface
Protein Atlas
(out of 14)
No. of Human
Cancer Cell
Types in CSPA
(out of 38)
No. of Human Pluripotent
Stem Cell Proteomic
Studies (out of 15;
Gundry et al., 2011)
Promoter
Occupancy
Nanog Oct4 Sox2
Reference Markers
ALPL C C C C 5 5 7 C
EPCAM (CD326) C C C C 1 4 7 C C
THY1 (CD90) C C C C C 6 22 5 C
Pluripotency Restricted
ADAM22 C < 1 13 2
ADCYAP1R1 C C 0 0 0
AMIGO3 C C 0 0 1
APLP2 C 0 22 3 C
ARHGAP28 C 0 0 3
ASTN1 C C 0 0 0 C C
ATP13A3 C C C 0 0 2
ATP6V0A2 C C 1 16 5
B4GALT3 C C C 1 11 1
C11ORF87 C 0 0 0
CACNG8 C C C 0 0 0 C
CALCR C C 1 0 0 C
CCKBR C C 1 0 1 C
CD83 C 0 17 0
CDH3 C C C 1 1 3
CELSR2 C C C 1 6 1
CHST6 C 1 6 0
CLECL1 C 0 0 0
CLUL1 C 0 0 0 C
CNTFR C C C C 1 3 0 C
CNTN2 C C 1 0 0
CPSF3L C 1 0 1
DBC1 C 0 0 0 C
DPEP1 C C 1 2 0 C
DPP6 C C 0 0 0 C C
EFNA3 C <a C 0 0 0
ELFN1 C C 1 9 1
(Continued on next page)
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Table 1. Continued
Gene Symbol
for Protein
Mouse
ESC
Mouse
iPSC hESC hiPSC
Human
Fibroblasts
No. of Nondisease
Human Cell Types
in Cell Surface
Protein Atlas
(out of 14)
No. of Human
Cancer Cell
Types in CSPA
(out of 38)
No. of Human Pluripotent
Stem Cell Proteomic
Studies (out of 15;
Gundry et al., 2011)
Promoter
Occupancy
Nanog Oct4 Sox2
ENTPD2 C C C 1 3 1
EPHA7 C 1 0 0 C
FAM216A C 0 0 0
FGFR4 (CD334) C C 1 5 1
FKRP C C C 0 11 2
FLT1 C C 0 1 1 C
FTH1 C 1 0 1
GABRA3 C C 0 0 0
GABRA5 C 0 0 1 C
GABRB3 C C 0 1 3
GCNT2 C 0 0 3 C C C
GDPD2 C C 1 0 0 C C
GNPTAB C C C 1 22 4 C
GPM6A C 0 0 0 C
GPR20 C C 0 0 0
GPR64 C C 1 2 0
GPR98 C C 0 0 0 C C C
GRID2 C C 0 0 0 C C C
HEPH C C 1 0 0
HPN C 0 0 0
HTR2C C C 0 0 0
IGSF1 C C 1 2 2 C
IGSF21 C C 0 0 1
IGSF9 C C 0 0 2 C
IL17RD C C C C 1 5 0 C C C
IL27RA C C 0 9 1
IL4R (CD124) C C 1 7 2
INHBE C C 1 2 0
KAL1 C C 0 0 0
KCNE1L C C 1 0 0
KCNE3 C C 0 3 0
KDR (CD309) C C 1 0 3
(Continued on next page)
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Table 1. Continued
Gene Symbol
for Protein
Mouse
ESC
Mouse
iPSC hESC hiPSC
Human
Fibroblasts
No. of Nondisease
Human Cell Types
in Cell Surface
Protein Atlas
(out of 14)
No. of Human
Cancer Cell
Types in CSPA
(out of 38)
No. of Human Pluripotent
Stem Cell Proteomic
Studies (out of 15;
Gundry et al., 2011)
Promoter
Occupancy
Nanog Oct4 Sox2
KIT (CD117) C C C 1 1 2 C
LAMA1 C C C C 1 9 6 C
LAMB2 C C C 1 2 2 C
LGR4 C C 1 0 2 C
LINGO1 C C 1 0 1 C C C
LPAR3 C C 0 0 0 C C
LPAR4 C C C C 1 0 1 C
LRIG1 C 1 0 4 C C C
LRP4 C C C C 1 4 3 C C
LRRN1 C C 1 4 3 C C C
MC5R C 0 0 0
MEGF10 C 0 0 0 C C
MFSD11 C C 0 0 0
MICB C C 1 9 1 C
MMGT1 C C 0 1 5
MMP15 < C 1 0 0 C C
NCLN C C C 0 1 6
NLGN4X C C 0 3 2
NPR1 C C C 1 1 0
NPY1R C C 1 1 1
NRXN1 C C 0 0 0 C
NTN1 C 1 0 0 C C C
OLFM2 C 0 0 0 C
OLFM4 C 0 0 0
OLFML3 C C 0 4 1 C C C
PCDH11X C C 0 0 1
PLA2G3 C 0 1 1 C
PLXDC2 C C C 0 0 1 C
PODXL2 C C 1 6 1
PTPRD C 0 3 3
PTPRU C 0 0 2 C
PTPRZ1 C C C 0 5 4 C C
(Continued on next page)
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Table 1. Continued
Gene Symbol
for Protein
Mouse
ESC
Mouse
iPSC hESC hiPSC
Human
Fibroblasts
No. of Nondisease
Human Cell Types
in Cell Surface
Protein Atlas
(out of 14)
No. of Human
Cancer Cell
Types in CSPA
(out of 38)
No. of Human Pluripotent
Stem Cell Proteomic
Studies (out of 15;
Gundry et al., 2011)
Promoter
Occupancy
Nanog Oct4 Sox2
SEMA4B C C C C 1 16 1 C
SEMA6A C C 0 0 6 C C
SLC15A1 C C C 0 0 1
SLC15A2 C C 0 1 0 C C
SLC24A3 C 1 0 0 C C C
SLC2A12 C 0 1 0 C C C
SLC30A4 C 0 0 0
SLC38A2 C C C C 1 0 4
SLC38A5 C 0 0 2
SLC38A9 C C C 1 2 2
SLC43A1 C C C 1 6 1
SLC6A5 C C 0 0 0 C
SLC7A3 C C C 1 0 6
SLITRK4 C C 0 3 2
SPINT1 C C C C 1 0 3
ST14 C C C C 0 6 1
STX1B C < 1 0 2
TLR2 (CD282) C < C 1 6 0 C
TMEM114 C C 1 0 0 C
TMEM132B C 1 1 1 C C
TMEM200B C 1 3 1 C C
TMEM63A C 1 3 3
TMEM63C C C 1 3 0
TNFRSF10C
(CD263)
C 0 0 0
TNFRSF21 C 0 4 1 C C
TNFRSF8
(CD30
C C 1 10 2
TNFSF11
(CD254)
C C 0 0 0
UNC5D C C 0 0 1 C
VSIG10 C C C C 1 5 2 C
VSIG10L C C 0 0 0
WBSCR17 C C C < 0 1 2
(Continued on next page)
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Table 1. Continued
Gene Symbol
for Protein
Mouse
ESC
Mouse
iPSC hESC hiPSC
Human
Fibroblasts
No. of Nondisease
Human Cell Types
in Cell Surface
Protein Atlas
(out of 14)
No. of Human
Cancer Cell
Types in CSPA
(out of 38)
No. of Human Pluripotent
Stem Cell Proteomic
Studies (out of 15;
Gundry et al., 2011)
Promoter
Occupancy
Nanog Oct4 Sox2
Pluripotency: Putative Negative Markers
ANPEP (CD13) C C C 7 14 2
BTN3A3 C 9 24 0
COLEC12 C C C 7 11 1
DPP4 (CD26) C 9 16 1 C C
EMR2 (CD312) C 7 21 0
FAP C 6 12 1 C
FBN1 C 6 8 2
GPR126 C C 6 13 0
ICAM5 C 6 23 0
NRP1 (CD304) C C C 8 19 0 C
PLAUR C 6 20 1 C
PRNP (CD230) C C C 10 37 2
PTPRM C C 7 12 1
Pluripotency restricted were identified in one or fewer nondiseased cell types from the Cell Surface Protein Atlas. Negative markers were identified in human
fibroblasts and six or more nondiseased cell types from the Atlas, but not in human pluripotent cells. Mouse ESC and iPSC data are from Gundry et al. (2012).
aFor the hESC and hiPS surface protein data from the current study, ‘‘<’’ indicates the protein was identified with a probability of <0.5 in that data set.
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Human Pluripotent Stem Cell Surfaceomediscrepancies observed between the transcriptome ana-
lyses and theCSC technology data.We observed fourmem-
bers of this family (SLC2A1 [GLUT1], SLC2A3 [GLUT3],
SLC2A4 [GLUT4], and SLC2A12 [GLUT12]) in hESCs and
hiPSCs via the CSC technology, of which three are summa-
rized in Figure 5A. Surface expression ofGLUT1 andGLUT4
were observed by flow cytometry or immunocytochem-
istry (Figures 5B and 5C). By microarray, GLUT3 mRNA is
three to five times higher than that of GLUT1 (Figure 5A),
an observation validated by quantitative real-time PCR
(Figure S2); however, significantly more MS/MS spectra
for GLUT1 (487 MS/MS spectra in hESC) were observed
than for GLUT3 (41 spectra) and GLUT4 (32 spectra) (Fig-
ure 5A). Protein sequences for GLUT1, GLUT3, and
GLUT4 each contain a single site of N-glycosylation
(UniProt) and were identified by one unique peptide
sequence, whereas GLUT12 was identified by a single pep-
tide containing three of the four possible N-glycosylation
sites. Of course, the comparison of the total number of
MS/MS spectra identified is only a crudemeasure of relative
protein abundance, and it is typically inappropriate to
apply spectral counting methods for relative abundance
among different proteins within a sample (rather than194 Stem Cell Reports j Vol. 3 j 185–203 j July 8, 2014 j ª2014 The Authorsone protein among multiple samples) due to variation in
number of tryptic peptides that could result from different
protein sequences. Moreover, changes in glycan structure
could affect our ability to efficiently capture N-glycopep-
tides.Despite these caveats and in contradiction to the tran-
scriptomic data, the relative number of spectra identified
for GLUT1, GLUT3, and GLUT4 may reflect an authentic
difference in surface abundance among these proteins
because only a single peptide sequence is expected and
explains why this protein family came to our attention.
Knowing that GLUT1 is critical in early mouse embry-
onic development (Chi et al., 2000; Mobasheri et al.,
2005), these observations prompted us to address whether
surface expression of GLUT1 is required for hPSC biology
using the chemical STF-31, a reported GLUT1 inhibitor
(Chan et al., 2011). The media from STF-31-treated hPSCs
do not show visible changes in pH during the first 48 hr
of treatment, relative to vehicle controls, confirming that
overall cell metabolism is reduced (Figure S2). Although
human mesenchymal stem cell (MSCs), hESC-cardiomyo-
cytes (CMs), and hFibs exhibit no adverse effects to
STF-31 treatment at any time point examined (Figure 5D),
treatment with STF-31 results in 80% cell death in hPSC by
Figure 3. Immunocytochemistry of DF6-6-9T hiPS Cells Stained with Surface Markers
(A) Surface marker labeling on fixed hiPSCs with inset showing overlay with OCT4.
(B) Surface markers labeling on live hiPSCs with inset showing overlay with Hoechst. Scale bar, 50 mm.
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Figure 4. Flow Cytometry Histograms of Live, Unfixed, H1 hESC, DF6-6-9T hiPSC, and hFib
(A) Reference markers.
(B) Positive hPSC selection markers.
(C) Negative markers.
See also Figure S1.
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Human Pluripotent Stem Cell Surfaceome48 hr and100% cell death by 72 hr (Figure 5E). Following
72 hr treatment, culture dishes of hiPSCs and hESCs were
examined for up to 5 days post-treatment, and no viable
cells were detected (data not shown). Successful elimina-
tion of hPSCs was observed regardless of cell density
(30%–100% tested; data not shown). To further assess the
selectivity of STF-31 for hPSCs, we established cocultured
hESCs and hFibs (seeded 50:50; maintained on Matrigel
for 4 days prior to treatment). Following 72 hr of STF-31
(2.5 mM) treatment, OCT4 expression was undetectable
by flow cytometry and immunocytochemistry, whereas
the fibroblast marker DPP4 was unaffected (Figure 5F, top
and middle). Quantitative real-time PCR analyses of the
treated coculture confirmed these findings, where the
fibroblast markers DPP4 and NRP1 exhibit a relative
increase (due to loss of hPSCs) and pluripotency markers
(OCT4 and NANOG) are reduced to background levels (Fig-
ure 5F, bottom). STF-31 could also be added to mixed cul-
tures without killing hPSC-derived differentiated progeny.
To demonstrate this, we generated monolayers of hESC-196 Stem Cell Reports j Vol. 3 j 185–203 j July 8, 2014 j ª2014 The Authorsderived cardiomyocytes, which in our hands are 98%
TNNT2+ by day 10 of differentiation (Figure 5G). After
72 hr of STF-31 (2.5 mM) treatment, we were unable to
detect any effects on spontaneous contraction (rate or
frequency) and by quantitative real-time PCR, cardiac tran-
scripts NKX2.5 decreased from day 10 to day 13, whereas
TNNT2 positivity remained constant. These results were
indistinguishable from vehicle controls (Figure S2), thus
indicating that STF-31, although toxic to hPSCs, spares a
wide variety of progenitor and differentiated cells. There-
fore, this resource also provides a ‘‘look-up directory’’ for
the potential repurposing of drugs based on the direct
knowledge of cell-surface protein abundance.DISCUSSION
Until the recent development of proteomic technologies
for the direct measurement of the pool of cell-surface-
exposed proteins such as the CSC technology, researchers
Stem Cell Reports
Human Pluripotent Stem Cell Surfaceomehad to rely on antibody-based probes for the sequential
verification of cell-surface proteins. Microarray data
partially enabled the inference of cell-surface expressed
proteins, but discrepancies with flow cytometric data
showed that posttranscriptional regulatory mechanisms
need to be considered in order to obtain insights into the
quantities of proteins in certain locations at a particular
point in time. Thus, researchers lack a comprehensive
and reliable resource of cell-surface exposed proteins for
most human stem cells and progeny. Here, we directly
measured the N-glycoprotein cell-surface proteome of
hESCs and hiPSCs and provide an experimentally verified
resource for the selection of lineage markers, markers for
cell isolation, and the selection of reagents for the charac-
terization of new hiPSC lines. Together with our analysis
of hFibs, we have identified 719 surface proteins including
496 on hPSCs. Many of the identified proteins are barely
detectable at the mRNA level depending on thresholds
set forth or lack commercially available and validated anti-
bodies that preclude their identification in antibody-based
screens. Moreover, our analysis of the transcriptionally
defined cell-surface proteome as predicted based on GO
term annotations illustrate the limitations in relying solely
on sometimes predicted annotations and transcriptional
signals.
A genome-scale location analysis using published data
(Gifford et al., 2013) was performed to identify surface pro-
teins that have promoters occupied by POU5F1(OCT4)/
SOX2/NANOG (OSN). In total, 30 (6%) of the 496 proteins
identified on the surface of hPSCs have promoters occupied
by OSN (Table S7). An additional 47 were occupied by two
factors. Of the 206 hPSC-restricted proteins, 16 (7%) are
occupied by OSN. Transcriptional dogma would suggest
that promoters occupied by OSN are critical to pluripo-
tency, and the surface data are consistent with this fact,
because none of the putative negative markers were occu-
pied by OSN and only five of the hFib restricted were occu-
pied byOSN. Although a direct role in pluripotency has not
yet been described for these 16 OSN occupied PSC-
restricted proteins, several have been implicated in early
developmental processes or mechanisms with relevance
to pluripotency, including CXADR (Dorner et al., 2005),
GPR98 (McMillan et al., 2002), IL17RD (Torii et al., 2004),
LINGO1 (Mi et al., 2004), LRIG1 (Laederich et al., 2004),
and LRRN1 (Hossain et al., 2008).
In the HSC field, immunophenotyping with antibodies
has been critical to the evaluation of cell-surface proteins
as surrogate markers of potency, function, immunological
compatibility, and for the isolation of cells for therapeutic
purposes. As we (Gundry et al., 2011, 2012) and others
(Kahler et al., 2013; Kang et al., 2011; Manos et al., 2011)
have demonstrated, accessible surface proteins are useful
as markers for sorting and characterizing pluripotent cells.SteApplication of the positive selection hPSC markers
described in this resource provides the field with new tar-
gets suitable for improving the efficiency of isolation and
characterization of high quality hiPSC colonies and/or
those with defined differentiation potential. In addition
to the positive PSC markers, these data reveal fibroblast
markers (DPP4, NRP1, and COLEC12) useful for negative
selection of hiPSCs from reprogrammed fibroblasts. Addi-
tional negativemarkers are likely to emerge as the cell types
within the Cell Surface Protein Atlas expands or if less strin-
gent data filtering are used (i.e., only require presence in
hFib and absence in hPSCs, regardless of expression among
other cell types). Precise mapping (time and quantity) of
transcriptional and protein levels of these putative nega-
tive markers during reprogramming will ultimately influ-
ence the utility of these accessible proteins for selection
purposes. The major bottleneck in using surface proteins
for isolation and cell characterization is the lack of suitable
antibodies or other affinity reagents that recognize native
extracellular epitopes, a requirement for live cell selection.
The information generated in this study partially overcome
this limitation as the CSC technology experimentally
verifies N-glycosylated peptides present in extracellular
exposed domains of transmembrane and GPI-anchored
proteins, which directly facilitates antigen design of surface
epitopes useful for antibody production. Therefore, CSC
technology lends itself for the immunophenotyping of
cells without antibodies.
The hPSC surface proteome resource described here can
be further exploited to rationally identify accessible and
putative drug targets on the surface of hESCs and hiPSCs.
This might be especially useful for repurposing known
drugs. Although GLUT1 is present on many cell types,
hPSCs, unlike many other cells that often contain multiple
glucose transporters or rely on oxidative phosphorylation,
are believed to be highly reliant on glycolysis, analogous to
the Warburg effect in cancer cells (Folmes et al., 2011;
Varum et al., 2011). Of the cells tested in this study, the
reported GLUT1 inhibitor STF-31 proved to be selectively
toxic to hPSCs. Recently, using a small molecule screening
approach, Ben-David et al. (2013a) discovered the utility of
a small molecule inhibitor of oleic acid biosynthesis, Pluri-
SIn, with selective toxicity for hPSCs. Although it is known
that metabolism influences a cell’s decision to proliferate,
differentiate, or remain quiescent (Shyh-Chang et al.,
2013), these two studies firmly establish that small mole-
cule-basedmetabolic inhibitors represent viable alternative
strategies to suicide genes (Cao et al., 2007; Rong et al.,
2012), SSEA-5, lactate, and Claudin-6-based approaches
(Ben-David et al., 2013b; Tang et al., 2011; Tohyama
et al., 2013). Furthermore, because another reported small
molecule inhibitor of GLUT1 that we tested, WZB117,
also proves toxic to hPSCs (data not shown), the use ofm Cell Reports j Vol. 3 j 185–203 j July 8, 2014 j ª2014 The Authors 197
Figure 5. STF-31 Studies
(A) Table of the number of MS/MS spectra identified via the CSC technology and the microarray values for three GLUT transporters in H9
hESCs and KB3 hiPSCs.
(B) Immunofluorescence image of GLUT4 on DF6-9-9T hiPS showing surface localization, and inset shows overlay with OCT4. Scale bar,
50 mm.
(legend continued on next page)
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Human Pluripotent Stem Cell Surfaceomeother strategies to specifically inhibit GLUT1 may be
broadly applicable for the removal of tumorigenic hPSCs
from cultures of differentiating cells. In contrast to the pre-
vious reports that required alternative energy sources
(Tohyama et al., 2013; Tomizawa et al., 2013), our study
achieves selective hPSC elimination without alternative
fuel substrates or general glucose starvation, making our
findingsmore broadly useful to the community than previ-
ous approaches.
The comprehensive and dynamic single cell hPSC sur-
face proteome is a work in progress. The analyses used
here to identify hPSC-restricted proteins are based on infor-
mation currently available in our Cell Surface Protein
Atlas (D.B.-F., A. Hofmann, T. Bock, A. Frei, F. Cerciello,
A. Jacobs, H.Moest, U. Omasits, R.L.G., C. Yoon, R. Schiess,
A. Schmidt, P. Mirkowska, A. Ha¨rtlova´, J. van Eyk,
J. Bourquin, R. Aebersold, K.R.B., P. Zandstra, and B.W.,
unpublished data). Because this database expands and
includes cell types from more developmental stages and
lineages, classifications for some proteins may change,
resulting in some of the hPSC-restricted proteins identified
here being reclassified as nonrestricted, as well as new
hPSC-restricted (positive and negative) markers coming
to light. As we have learned from comparisons made
possible by the Cell Surface Protein Atlas as well as the
work from the hematopoietic cell field, we recognize that
individual surface proteins are generally not restricted to
a single cell type, and that is the reason we also considered
proteins that were ‘‘relatively’’ restricted to hPSCs (in fewer
than three other cell types) in addition to the truly
restricted as a way to broaden the scope and bring more
potential markers to light. Thus, this resource serves as a
step toward defining surface protein and antibody panels
more selective for authentic pluripotent cells. Second, as
with any discovery-based mass spectrometry analysis of
complex samples, the failure to identify a protein in a(C) Flow cytometry histograms of live cells illustrating surface localiz
(D) Phase contrast images of hESCs, hiPSCs, hMSCs, hFibs, and hES-CMs
by 48 hr and 100% PSC death by 72 hr. Scale bar, 100 mm.
(E) Cell viability via neutral red assay of H1 hESCs and DF6-9-9T hiPSCs
average of three biological replicates, and error bars represent SEM. F
p values for the H1 data are shown.
(F) hESC/hFib coculture treated with STF-31 shows selective loss of
untreated hESC/hFib coculture (blue) and absence of OCT4 staining i
bright-field and immunofluorescence images of hESC/hFib coculture
fibroblast marker DPP4 and pluripotency marker OCT4. Scale bar, 100 m
and GAPDH in hESC/hFib coculture treated with STF-31 for 72 hr comp
biological replicates are shown, and error bars represent SEM.
(G) Left: flow cytometry histograms of day 11 hESC-CMs for TNNT2 a
differentiation of hESCs. Right: quantitative real-time PCR of cardiac
day 10 of differentiation) with STF-31, indicating no adverse effects
untreated (Figure S2). Results from triplicate technical analyses of tw
hESC. See also Figure S2.
Steparticular sample is not conclusive evidence that the pro-
tein is absent, due to the limitations in peptide sampling
in the instrument. This is a well-recognized limitation in
mass-spectrometry-based discovery approaches (Gingras
et al., 2005) and can be exacerbated in the case of low abun-
dance proteins (e.g., cell-surface proteins). Thus, the few
putative differences between hESCs and hiPSCs based
only on CSC technology data are not emphasized here
but are included in Table S1 for completeness. Third, prote-
omic technologies are valuable for describing the average
proteome present at a selected point in time ormore simply
a snapshot of proteins present on the cell surface at time of
labeling. However, the presence of a protein or change in
abundance of a protein with perturbation does not inher-
ently reflect the biological relevance of the protein for a
particular cell type. Nevertheless, it is predicted that pro-
teins such as IL17RD, LINGO1, and LRRN1, which are
among the most restricted to hPSCs, present in highest
levels, and have promoters occupied by OSN, will be
included as high-priority candidates going forward. Of
note for functional relevance are LINGO1 and IL17RD as
they are linked with inhibitory functions that may
contribute to themaintenance of the undifferentiated state
of PSCs. Moreover, although this data set is restricted to
N-linked glycoproteins, it is predicted that 90% of all
cell-surface proteins are predicted to be glycosylated
(Apweiler et al., 1999), and thus these data should repre-
sent a majority of the surface proteins present.
In conclusion, application of the CSC technology
provides direct evidence of the pool of N-glycoproteins
detectable at the hPSC surface. The bioinformatics strategy
chosen based on the integration of disparate data sets
provides a good filtering mechanism for the identification
of sensible candidates for practical (i.e., immunopheno-
typing) and functional studies, not only for the hPSC pop-
ulations studied here, but for a broad range of other stemation of GLUT1 on the surface of hESCs and hiPSCs.
after treatment with 2.5 mM STF-31, showing significant hPSC death
treated with 2.5 mM STF-31 compared to vehicle control. Data are an
or 48, 72, and 96 hr treatment, all p values are below 0.05, and the
hPSCs. Top: flow cytometry histograms showing OCT4 staining of
n hESC/hFib coculture treated for 72 hr with STF-31 (red). Middle:
untreated (left) or treated (right) with STF-31 for 72 hr, showing
m. Bottom: quantitative real-time PCR of OCT4, NANOG, DPP4, NRP1,
ared to untreated. Results from triplicate technical analyses of two
nd MLC2V, illustrating high-quality hESC-CMs obtained by in vitro
genes NKX2.5 and TNNT2 in hESC-CMs treated for 72 hr (starting on
on the expression of these genes by the inhibitor as compared to
o biological replicates are shown and are normalized to untreated
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or inhibitors selected based on our resource could be
further exploited for the depletion of cell populations in
a heterogeneous cell context, such as shown here for the
depletion of pluripotent cells, without the expense of a
large-scale screen or gene targeting approaches. This pro-
tein-centric resource provides experimental evidence for
location-specific proteins which, when further developed
in the form of surface protein ‘‘barcodes’’ (Gundry
et al., 2011), might help to delineate cellular lineages
even further based on quantitative panels of cell-surface
markers. A detailed understanding of the functional roles
of the detected cell-surface markers in developmental and
environmental interactions is certainly a prerequisite to
understanding hiPSCs and ensuring their reproducible
production for therapeutic purposes. Going forward, this
technology and the resource described here will serve as a
platform for future comparisons of stem cells of other
origins.We acknowledge that extensive work will be neces-
sary to refine the protein candidates described in this
resource to arrive at the most effective and informative
markers for isolating the highest quality pluripotent cells.
This resource, which contains >100 proteins not previously
described on the surface of hPSCs, should therefore provide
a major step in a series of studies designed to define the
optimum marker combinations for high throughput
isolation and quality control studies of hPSCs.EXPERIMENTAL PROCEDURES
Cell Culture
Generation of hiPSCs, cultivation of hiPSCs (KB3, DF6-9-9T
[WiCell], hiPSC2a [Si-Tayeb et al., 2010]), hESC lines (H1, H9
[WiCell]), hFibs, bone marrow-derived mesenchymal stem cells
(hMSCs), and differentiation of cardiomyocytes are described in
the Supplement Information. The CSC technology was applied
to H9 hESCs and KB3 hiPSCs. The flow cytometry and immuno-
fluorescence staining were performed on DF-6-9T hiPSCs and
H1 hESCs.
Cell-Surface Capture: CSC Technology
Approximately 0.6-1E8 cells per biological replicate (nR 3) of H9
hESCs, KB3 hiPSCs, and hFibs were taken through the CSC
technology workflow as reported previously (Gundry et al., 2009,
2012; Hofmann et al., 2010; Wollscheid et al., 2009) with details
provided in the Supplemental Information.
STF-31 Studies
Cells were treated with 0, 2.5, and 5 mM STF-31 (4-[[[[4-(1,1-
Dimethylethyl)phenyl]sulfonyl]amino]methyl]-N-3-pyridinylben
zamide, Tocris Bioscience) for 96 hr to test cell viability with treat-
ment. RNA was collected for quantitative real-time PCR, or cells
were stained for DPP4 or OCT4. Day 10 hESC-CMs were treated
for 48 hr with 0, 2.5, and 5 mM STF-31 treatment, and RNA was200 Stem Cell Reports j Vol. 3 j 185–203 j July 8, 2014 j ª2014 The Authorscollected at 72 hr (day 13 of differentiation) for quantitative real-
time PCR analysis of TNNT2 and NKX2.5. In vitro cell toxicity
was determined using a neutral red uptake assay as previously
described (Steer et al., 2006).
Transcriptome Data
Microarray data were obtained in two laboratories on H9,
HiPSC2a, and KB3 cells, as described in the Supplemental Infor-
mation. To obtain a single expression value for visualization in
Figure 2, values for a single probe were averaged among all H9
and KB3 replicates analyzed using the Illumina system; if multi-
ple probes per gene were measured, only the highest value was
included.
Quantitative Real-Time PCR, Flow Cytometry, and
Immunocytochemistry
Details are provided in the Supplemental Information and
Table S8.
ACCESSION NUMBERS
The Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo/) accession number for the microarray data reported in this
paper is GSE55805.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experi-
mental Procedures, two figures, and eight tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.2014.
05.002.
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